Related Experiment Video

Updated: Aug 24, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Utilizing tumor hypoxia to enhance oncolytic viral therapy in colorectal metastases

Maura Reinblatt1, Richard H Pin, Howard J Federoff

  • 1Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Annals of Surgery
|May 29, 2004
PubMed
Abstract

Insights

Hypoxia-induced ribonucleotide reductase (RR) production enhances oncolytic herpes virus therapy. Combining G207 virus with RR under hypoxic control significantly reduces colorectal cancer tumor burden.

Area of Science:

  • Oncolytic virotherapy
  • Cancer biology
  • Gene therapy

Background:

  • Hypoxia is prevalent in tumors, contributing to treatment resistance and metastasis.
  • Oncolytic viruses, like G207 herpes virus, selectively target and destroy cancer cells.
  • G207 is deficient in ribonucleotide reductase (RR), a key enzyme for viral replication.

Purpose of the Study:

  • To investigate the impact of hypoxia-induced RR production on the efficacy of oncolytic herpes virus therapy.
  • To engineer a hypoxia-responsive system to boost viral replication in tumor microenvironments.

Main Methods:

  • Constructed a hypoxia-responsive enhancer (10xHRE) linked to the RR gene (UL39).
  • Transfected CT26 colorectal cancer cells with 10xHRE-UL39 and infected with G207 under varying oxygen conditions.
  • Evaluated cytotoxicity in vitro and tumor reduction in a murine colorectal cancer liver metastasis model.

Main Results:

  • Hypoxia significantly upregulated luciferase expression via 10xHRE (33-fold).
  • Co-administration of 10xHRE-UL39 and G207 increased G207-mediated cytotoxicity by 87% in hypoxic conditions.
  • In vivo, this combination therapy reduced tumor weight by 66% and tumor nodules by 65% compared to G207 monotherapy.

Conclusions:

  • Hypoxia-driven RR production markedly enhances oncolytic viral cytotoxicity and reduces tumor burden.
  • The combination of G207 and hypoxia-controlled RR presents a potent therapeutic strategy for colorectal cancer, overcoming resistance to oncolytic virotherapy.

More Related Videos

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...